Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Mt. Pleasant, South Carolina Clinical Trials

A listing of Mt. Pleasant, South Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (133) clinical trials

This phase 2 study is a placebo-controlled, double-blind, parallel group study of four concentrations of SM04690 (0.03, 0.07, 0.15, and 0.23 mg per 2 mL injection) injected intraarticularly (IA) into the target knee joint of subjects with moderately to severely symptomatic osteoarthritis (OA). Based on previous studies of SM04690, key ...

Phase

1.13 miles

Learn More »

Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes

The objective of the current study is to investigate the efficacy and safety of BTI320 compared to placebo in addition to metformin and/or sulfonylureas on glycemic control over 12 weeks in subjects with type 2 diabetes mellitus. This is a randomized, placebo-controlled, double-blind, multi-center study with two treatment arms. Study ...

Phase

1.13 miles

Learn More »

A Trial for New Treatment of Adult Patients With Irritable Bowel Syndrome

500 subjects will be enrolled with a diagnosis of IBS as defined by Rome IV criteria will be classified into cohorts according to the Rome IV classification of IBS subtypes. Each cohort (Cohort C & Cohort D) will recruit 250 subjects who will randomly receive either Blautix or matching placebo ...

Phase

1.13 miles

Learn More »

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

PRIMARY OBJECTIVES: I. To evaluate the overall response rate (ORR) (confirmed and unconfirmed, complete and partial) with talazoparib (BMN 673) in HRRD Medivation (MDVN)-positive patients. SECONDARY OBJECTIVES: I. To evaluate investigator assessed progression-free survival (IA-PFS) and overall survival (OS) associated with therapy in HRRD MDVN-positive patients. II. To evaluate ORR, ...

Phase

1.13 miles

Learn More »

Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris

This will be a Phase 2, multicenter, randomized, double-blinded, dose-ranging, parallel arm comparison study in male and non-pregnant female subjects, 9 through 45 years of age (inclusive) with facial acne vulgaris. This dose-ranging study, intended to identify the dose(s), will consist of 7 study visits over 14 weeks:

Phase

1.13 miles

Learn More »

BMX-010 is thought to treat a wide variety of inflammatory disorders. The main purpose of this study is to learn about the safety of the study drug. The primary purpose is to determine how much and how often BMX-010 can be safely given to patients with AD or PS. We ...

Phase

1.5 miles

Learn More »

CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders

Due to sustained military conflicts in Afghanistan and Iraq over the past decade, there are an increasing number of U.S. military personnel and Veterans returning home with posttraumatic stress disorder (PTSD) and comorbid alcohol use disorders (AUD) and substance use disorders (SUD). If left untreated, Veterans with co-occurring PTSD and ...

Phase

6.7 miles

Learn More »

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters

Phase

7.1 miles

Learn More »

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for head and neck cancer. The standard of care treatment will include surgery followed by radiation for 6 ...

Phase

7.1 miles

Learn More »

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

To estimate the clinical benefit of cemiplimab monotherapy for patients with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC) (Groups 1 and 3) or with unresectable locally advanced CSCC (Group 2), or with advanced CSCC [metastatic (nodal or distal) or unresectable locally advanced] treated (Group 4) as measured by ...

Phase

7.1 miles

Learn More »